| Literature DB >> 36034174 |
Meina Yue1, Di Liu1, Xiaoyu Li1, Shurui Jin2, Xue Hu1, Xinfeng Zhao1, Yidong Wu1.
Abstract
Purpose: This research investigated the dynamics of antibiotic resistance in Salmonella and the epidemiology of Salmonella infection in children. These data can aid in the prevention and control of the Salmonella epidemic and the diagnosis and treatment of salmonellosis.Entities:
Keywords: Salmonella; antibiotic resistance; children; epidemiology; serotype
Year: 2022 PMID: 36034174 PMCID: PMC9416490 DOI: 10.2147/IDR.S374658
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Figure 1The number of Salmonella isolates from patients of different ages. The bar chart shows the number of Salmonella infection cases and the invasive or non-invasive status of infections among various age groups of patients in Hangzhou from April 2006 to December 2021. Red bar: The median age.
Figure 2Distribution of 2099 Salmonella isolates by month from April 2006 to December 2021.
Clinical Presentation of Children with Invasive Infections and Non-Invasive Infections
| Clinical Presentation | Invasive Infections (n = 30) | Non-Invasive Infections (n = 2069) | ||
|---|---|---|---|---|
| Gastroenteritis | 11 (36.7%) | 1781 (86.1%) | 53.935 | <0.001 |
| Sepsis | 1 (3.3%) | 212 (10.2%) | 0.885 | 0.347 |
| Respiratory infections | 10 (33.3%) | 152 (7.3%) | 24.509 | <0.001 |
| Convulsion | 3 (10.0%) | 20 (1.0%) | 14.711 | <0.001 |
The Annual Rates of Salmonella Isolation from Stool
| Year | No. of Stool Samples | No. of | Rate (%) of | Total Stool Samples | Total | Average Rate (%) | ||
|---|---|---|---|---|---|---|---|---|
| 2006 | 231 | 15 | 6.49 | 8931 | 337 | 3. 77 | 464. 796 | 0. 000 |
| 2007 | 209 | 14 | 6.7 | |||||
| 2008 | 244 | 15 | 6.15 | |||||
| 2009 | 699 | 21 | 3 | |||||
| 2010 | 1036 | 34 | 3.28 | |||||
| 2011 | 1399 | 47 | 3.36 | |||||
| 2012 | 1703 | 48 | 2.82 | |||||
| 2013 | 3410 | 143 | 4.19 | |||||
| 2014 | 799 | 108 | 13.52 | 14,399 | 1732 | 12. 03 | ||
| 2015 | 1330 | 156 | 11.73 | |||||
| 2016 | 1063 | 134 | 12.42 | |||||
| 2017 | 1703 | 194 | 11.39 | |||||
| 2018 | 1848 | 210 | 11.36 | |||||
| 2019 | 2028 | 240 | 11.83 | |||||
| 2020 | 2518 | 316 | 12.55 | |||||
| 2021 | 3110 | 374 | 12.03 |
Figure 3The number of Salmonella Group B and Group D isolates by age in Hangzhou, China, from April 2006 to December 2021. The inset shows the number of S. Typhimurium and S. Enteritidis isolates by age.
Comparison of the Proportion of Group B and Group D and of S. Typhimurium and S. Enteritidis Isolates Before and After 4 Years of Age
| Variables | ≤4 Years | >4 Years | p | |
|---|---|---|---|---|
| Group B | 80.1% (1153/1440) | 40.4% (95/235) | 167.169 | <0.001 |
| Group D | 19.9% (287/1440) | 59.6% (140/235) | ||
| Typhimurium | 20.4% (190/933) | 61.7% (100/162) | 121.3 | <0.001 |
| Enteritidis | 79.6% (743/933) | 38.3% (62/162) |
Figure 4Distribution of serogroups and serotypes by year. The different colours represent different serotypes. The figure shows the number of isolates.
Distribution of Serogroups, Serotypes and NTS in Invasive Infection Cases
| Group (No.) | Serogroup | Serotype | No. |
|---|---|---|---|
| NTS (18) | B# | Typhimurium | 3 |
| B# | Stanley | 3 | |
| C1# | Choleraesuis | 3 | |
| C2 | Group C2* | 3 | |
| D# | Enteritidis | 2 | |
| D# | Derby | 1 | |
| D# | Dublin | 1 | |
| E1 | Group E1* | 2 | |
| Typhoidal (3) | A | Paratyphi A | 1 |
| B# | Paratyphi B | 1 | |
| D# | Typhi | 1 | |
| Untyped (9) | B# | Group B* | 2 |
| C1# | Group C1* | 1 | |
| D# | Group D* | 3 | |
| 3 | |||
| Total | 30 |
Notes: #The total number of Group B isolates was 9, the number of Group D isolates was 8, and the number of Group C1 isolates was 4. *Because Salmonella Group C2 and Group E1 do not contain typhoid Salmonella, they belong to NTS. While Salmonella Groups B, C1 and D included typhoid Salmonella, they could not be identified as NTS or typhoid, so they belonged to the untyped group.
Abbreviation: NTS, nontyphoidal Salmonella.
Figure 5Changes in antimicrobial resistance by year.
The Antibiotic Resistance Profiles of Four Serotypes
| Antibiotic | Typhimurium | Enteritidis | Stanley | Dublin | P | |
|---|---|---|---|---|---|---|
| CRO | 27.11% (77/284) | 20.88% (19/91) | 10.71% (3/28) | 22.22% (4/18) | 4.624 | 0.2 |
| FEP | 8.94% (32/358) | 7.27% (8/110) | 8.33% (3/36) | 12.00% (3/25) | 0.8815 | 0.83 |
| CAZ | 22.56% (81/359) | 23.85% (26/109) | 8.57% (3/35) | 22.22% (4/18) | 3.974 | 0.26 |
| AMP | 82.27% (297/361)a | 84.68% (94/111)a | 52.94% (18/34)b | 87.50% (21/24)a | 19.509 | <0.001c |
| SAM | 55.87% (200/358)b | 70.91% (78/110)a | 41.18% (14/34)b | 54.17% (13/24)a,b | 12.288 | 0.01d |
| TZP | 2.54% (9/354) | 0.91% (1/110) | 5.88% (2/34) | 0.00% (0/23) | 2.9022 | 0.32 |
| SXT | 44.38% (158/356)b | 8.18% (9/110)a | 34.29% (12/35)b | 24.00% (6/25)a,b | 49.768 | <0.001e |
| ATM | 16.91% (57/337) | 20.00% (22/110) | 12.90% (4/31) | 15.79% (3/19) | 1.045 | 0.79 |
| CIP | 19.61% (70/357)b | 1.83% (2/109)a | 8.57% (3/35)a,b | 0.00% (0/23)a,b | 26.782 | <0.001f |
| LEV | 4.63% (13/281) | 1.10% (1/91) | 0.00% (0/22) | 0.00% (0/18) | 2.4349 | 0.43 |
| MDR | 29.83% (108/362) | 18.92% (21/111) | 13.89% (5/36) | 12.00% (3/25) | 11.013 | 0.012g |
| IPM | 0.00% (0/275) | 0.00% (0/82) | 0.00% (0/33) | 0.00% (0/24) | – | – |
Notes: a,bEach subscript denotes a subset of serotype categories. cStatistically significant, comparing Stanley versus Typhimurium, Enteritidis and Dublin. dStatistically significant, comparing Enteritidis versus Typhimurium and Stanley. eStatistically significant, comparing Enteritidis versus Typhimurium and Stanley. fStatistically significant, comparing Typhimurium versus Enteritidis. gPairwise comparisons of the four serotypes did not reveal statistical significance based on corrected p values.
Abbreviations: CRO, ceftriaxone; FEP, cefepime; CAZ, ceftazidime; AMP, ampicillin; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; SXT, trimethoprim-sulfamethoxazole; ATM, aztreonam; CIP, ciprofloxacin; LEV, levofloxacin; MDR, multidrug resistance; IPM, imipenem.
Figure 6Analysis of antibiotic resistance in invasive and non-invasive infection isolates.